1. Introduction {#sec0001}
===============

Adequate screening for latent tuberculosis (TB) infection (LTBI) has become increasingly important in low TB-endemic countries such as The Netherlands, particularly due to a growing number of immigrants coming from high TB-endemic countries [@bib0001] and increasing use of immunosuppressive therapies [@bib0002]. For the diagnosis of LTBI the World Health Organisation (WHO) recommends using either the tuberculin skin test (TST) or interferon-gamma release assays (IGRA). In case of a positive TST or IGRA (either QuantiFERON Gold^®^ or T-SPOT.*TB*^®^ test) result, chest radiography (CXR) is indicated to evaluate for possible signs of active (subclinical) TB, followed by initiation of treatment for LTBI [@bib0003]. According to the Dutch national guideline regarding screening for LTBI before initiating immunosuppressive therapy, a CXR is always indicated regardless of immunological results [@bib0004]. From the literature it is known that certain allegedly characteristic abnormalities on CXR, such as (calcified) nodule(s), pleural thickening and/or fibrotic lesions, may be present in case of a prior *Mycobacterium tuberculosis (Mtb)* infection [@bib0005], [@bib0006]. Thus, the CXR could have additional value for LTBI screening. However, there are no validated criteria for interpretation of such abnormal findings on a CXR.

Both TST and IGRA, being dependent on the patient\'s immune system, can be false negative or indeterminate in patients with chronic diseases and/or immunosuppressed individuals [@bib0007], [@bib0008]. An advantage of the CXR is that abnormalities due to past infection are independent of the immune status. In previous studies, the prevalence of any of the mentioned radiological signs in individuals with LTBI ranged from 6.1% in a low TB-endemic area to 63.0% in a high TB-endemic area [@bib0009], [@bib0010], suggesting that repeated infections and/or higher infection burden may be associated with more detectable radiological lesions. Specific radiological signs such as non-calcified nodules and fibrotic lesions have been associated with a high risk of progression to active TB [@bib0005], [@bib0011], [@bib0012]. Most studies that assessed radiological signs of LTBI, however, lacked a control group of uninfected individuals. Three studies that did include a control group only referred to 'radiological abnormalities' but did not describe which lesions were assessed, nor were the radiologists blinded to the infection status of the study participants [@bib0011], [@bib0013], [@bib0014]. Thus, all past studies had a high risk of bias.

The aims of the present study were to assess the sensitivity and specificity of abnormalities previously reported as being suggestive for LTBI on CXR in individuals with or without LTBI. LTBI diagnosis was based on a positive QuantiFERON TB Gold In-tube^®^ (QFT) and/or TST. The radiological assessment was performed in a blinded fashion, in the sense that the reader was blinded to the QFT and TST results and the diagnosis.

2. Methods {#sec0002}
==========

2.1. Setting {#sec0003}
------------

All CXRs were performed at either Leiden University Medical Center (LUMC), which is a tertiary care teaching hospital, the occupational health service (OHS) or at the regional municipal health service (MHS). The protocol of this retrospective observational study using anonymised data was evaluated by the Medical Ethics Committee of LUMC and waived from the requirement of informed consent (protocol G16.105).

2.2. Study design {#sec0004}
-----------------

Data were retrieved between October 2016 and June 2018. Collected data included demographics, immigration status, Bacille Calmette-Guérin (BCG)-vaccination status, and, if available, relevant comorbidities, risk factors, reported TB contact, past TB, QFT results, TST results if available and microbiological results.

2.3. Study participants {#sec0005}
-----------------------

The study population has been previously described in a study which was focused on evaluation of QFT results near the cut-off [@bib0015]. The study population consists of 90 randomly selected individuals with a low-negative QFT result (\<0.15 IU/ml), 107 subjects with a borderline (0.15--0.35 IU/ml), 83 with a low positive (0.35--0.70 IU/ml and a random selection of 30 patients with a high-positive (≥0.70 IU/ml) QFT result. Excluded were individuals \<18 years old and those in whom no CXR had been performed. A flow diagram of the study population is shown in [Fig. 1](#fig0001){ref-type="fig"}.Fig. 1Overview of all included patientsNOTE. The selection of patients is described in detail in a previous publication [@bib0015].Abbreviations: QFT: QuantiFERON-TB Gold In-Tube; CXR: chest radiography.Fig. 1.

2.4. Classification criteria for LTBI {#sec0006}
-------------------------------------

Patients were considered *Mtb* infected in case of a positive QFT result (≥0.35 IU/ml) and/or positive TST, defined as induration ≥15 mm irrespective of BCG-vaccination status or ≥10 mm in BCG unvaccinated individuals or those vaccinated up to one year of age. *Mtb* infection was considered possible in case of a borderline QFT result (0.15--0.35 IU/ml) in association with a negative TST result, if performed, or with no TST performed. In a separate analysis, the criteria for LTBI were broadened to include immunological proof and/or all available evidence for an infection with *Mtb* including history and microbiological results.

2.5. Radiography {#sec0007}
----------------

Because the routine evaluation of the CXR investigations had often not primarily been focused on identification of characteristics of possible LTBI, all CXR were re-assessed by an expert thoracic radiologist (LK, who has \>20 years of experience in CXR evaluation). The radiologist was blinded to all data except for age and clinical history of lung diseases, and thus unaware of QFT and TST results and final clinical diagnosis. All CXRs, both posteroanterior and lateral, were evaluated for signs compatible with prior TB, being fibrous scarring (including size and presence of volume loss), pleural thickening, calcified nodules (including calcified lymph nodes) with size and number, and non-calcified nodules. STROBE guidelines for reporting observational studies were followed [@bib0016].

2.6. Statistical analysis {#sec0008}
-------------------------

Differences between categorical data were evaluated with chi square tests or Fisher\'s Exact Probability Test if appropriate. Sensitivity and specificity of abnormalities considered suggestive for LTBI on CXR were calculated. Continuous data were compared between groups using one-way ANOVA or nonparametrically with Mann-Whitney U or Kruskall-Wallis test as appropriate. Using two-sided testing, differences were considered significant at *p* \< 0.05. Statistical analysis was performed using IBM SPSS Statistics version 23 and GraphPad Prism 7.

3. Results {#sec0009}
==========

3.1. Study population {#sec0010}
---------------------

Of 293 selected patients, no CXR was available for 57 individuals. In the remaining 236 the CXR was reassessed. The characteristics of all 236 included individuals are shown in [Table 1](#tbl0001){ref-type="table"}. Roughly 75% originated from the hospital setting, the remaining 25% from the MHS/OHS. Patients from the hospital setting were significantly older, more often immunocompromised and had a higher frequency of TB-related abnormalities on CXR. Patients from the MHS/OHS were more frequently BCG vaccinated, TST positive and more often reported TB contact. The proportion of patients with LTBI was significantly higher in those originating from the MHS/OHS.Table 1Characteristics of the study population.Table 1Leiden University Medical CenterMunicipal or occupational health servicesAllCharacteristics*N* = 179*N* = 57*N* = 236*p* valueAge (y)51.7 ± 19.439.7 ± 14.048.8 ± 18.9\<0.001Sex (male)87/179 (48.6%)24/57 (42.1%)111/236 (47.0%)0.39Immigrant79/179 (44.1%)33/57 (57.9%)112/236 (47.5%)0.07 Sub-Saharan Africa11/79 (13.9%)6/33 (18.2%)17/112 (15.2%) North Africa14/79 (17.7%)4/33 (12.1%)18/112 (16.1%) Asia/Indonesia35/79 (44.3%)8/33 (24.2%)43/112 (38.4%) Middle and S. America10/79 (12.7%)1/33 (3.0%)11/112 (9.8%) Eastern-Europe/Russia1/79 (1.3%)0/33 (0%)1/112 (0.9%) Other8/79 (10.1%)14/33 (42.4%)22/112 (19.6%)Originating from a high TB-endemic country[a](#tb1fn1){ref-type="table-fn"}43/179 (24.0%)11/57 (19.3%)54/236 (22.9%)0.46Travel to TB-endemic country65/159 (40.9%)25/50 (50.0%)90/209 (43.1%)0.26Reported past active TB5/179 (2.8%)0/57 (0%)5/236 (2.1%)0.34treated4/5 (80.0%)0/0 (0%)4/5 (80.0%)Reported contact with active TB26/179 (14.5%)38/57 (66.7%)64/236 (27.1%)\<0.001Professional risk32/179 (17.9%)13/57 (22.8%)45/236 (19.1%)0.41Immunocompromised54/179 (30.2%)1/57 (1.8%)55/236 (23.3%)\<0.001BCG-vaccinated73/179 (40.8%)37/57 (64.9%)110/236 (46.6%)0.001TST performed87/179 (61.7%)54/57 (94.7%)141/236 (59.7%)\<0.001 TST ≥10 mm53/87 (60.9%)47/54 (87.0%)100/141 (70.9%)\<0.001QFT-GIT0.41 \<0.15 IU/ml52/179 (29.1%)12/57 (21.1%)64/236 (27.1%) 0.15--0.35 IU/ml63/179 (35.2%)20/57% (35.1%)83/236 (35.2%) ≥0.35 IU/ml64/179 (35.8%)25/57 (43.9%)89/236 (37.7%)LTBI (based on TST & IGRA[b](#tb1fn2){ref-type="table-fn"})0.006 No42/179 (23.5%)4/57 (7.0%)46/236 (19.5%) Possible52/179 (29.1%)3/57 (5.3%)55/236 (23.3%) Yes85/179 (47.5%)50/57 (87.7%)135/236 (57.2%)Any prespecified abnormality on CXR96/179 (53.6%)20/57 (35.1%)116/236 (49.2%)0.015[^1][^2][^3][^4]

3.2. Comparison between patients with LTBI and uninfected individuals {#sec0011}
---------------------------------------------------------------------

Patients classified as having LTBI were compared to those with possible LTBI (as based on only a borderline QFT result) and to those considered uninfected ([Table 2](#tbl0002){ref-type="table"}). Any prespecified abnormality on CXR was observed in 116/236 (49.2%) of all included persons, in similar frequencies among patients with LTBI, possible LTBI or no LTBI. Pleural thickening was the most prevalent abnormality (24.2%), but not different between groups. Fibrotic scarring, both with and without volume loss was even significantly more often observed in individuals without LTBI. However, a fibrotic scar ≥ 2 cm^2^ was observed in 27 patients, all of whom were diagnosed with LTBI or possible LTBI (*p* = 0.003). At least one calcified nodule ≥ 1.5 mm was observed in 25 patients, of whom 23 (92.0% \[95% CI: 74%−99%\]) were diagnosed with LTBI or possible LTBI (*p* = 0.002). Examples of a fibrotic scar ≥ 2 cm^2^ without and with a calcified nodule ≥ 1.5 mm are shown in [Figs. 2](#fig0002){ref-type="fig"} and [3](#fig0003){ref-type="fig"}, respectively. Both features were very specific but not sensitive for LTBI ([Table 3](#tbl0003){ref-type="table"}). Thus, positive findings were informative but absence of such lesions does not exclude LTBI. Four individuals had both a fibrotic scar ≥ 2 cm^2^ and a calcified nodule ≥ 1.5 mm, all of whom were diagnosed with either LTBI or possible LTBI. The frequency of non-calcified nodules did not differ between groups. If the criteria for LTBI were broadened including microbiological results and a positive history of latent or active TB, the results were not different.Table 2Radiological characteristics stratified by *Mtb* infection status.Table 2No LTBIPossible LTBI (borderline QFT only)LTBIAllCharacteristics*N* = 46*N* = 55*N* = 135*N* = 236*p* valueAge (y)49.0 ± 19.751.0 ± 21.247.8 ± 17.748.8 ± 18.90.55Sex (male)25/46 (54.3%)31/55 (56.4%)55/135 (40.7%)111/236 (47.0%)0.08Immigrant13/46 (28.3%)24/55 (43.6%)75/135 (55.6%)112/236 (47.5%)0.005BCG13/46 (28.3%)22/55 (40.0%)75/135 (55.6%)110/236 (46.6%)0.003Immunocompromised11/46 (23.9%)15/55 (27.3%)29/135 (21.5%)55/236 (23.3%)0.69Reported past active TB1/46 (2.2%)2/55 (3.6%)2/135 (1.5%)5/236 (2.1%)0.70 treated0/1 (0%)2/2 (100%)2/2 (100%)4/5 (80%)Reported contact with active TB6/46 (13.0%)11/55 (20.0%)47/135 (34.8%)64/236 (27.1%)0.007Past pulmonary diseases nonTB13/43 (30.2%)6/26 (18.8%)11/56 (19.6%)30/131 (22.9%)0.38 COPD/emfysema0/13 (0%)0/6 (0%)4/11 (36.4%)4/30 (13.3%) pneumonia nonTB6/13 (46.2%)3/6 (50.0%)5/11 (45.5%)14/30 (46.7%) other7/13 (53.8%)3/6 (50.0%)2/11 (18.2%)12/30 (40.0%)Prespecified signs of latent TB on CXR28/46 (60.9%)23/55 (41.8%)65/135 (48.1%)116/236 (49.2%)0.15 Fibrotic scar any size13/46 (28.3%)15/55 (27.3%)19/135 (14.1%)47/236 (19.9%)0.034 Fibrotic scar ≥ 2 cm^2^0/44 (0%)12/54 (22.2%)15/135 (11.1%)27/233 (11.6%)[a](#tb2fn1){ref-type="table-fn"}0.003 Fibrotic scar any size with volume loss11/46 (23.9%)9/55 (16.4%)13/135 (9.6%)33/236 (14.0%)0.046Calcified nodules8/46 (17.4%)9/55 (16.4%)18/135 (13.3%)35/236 (14.8%)0.75 Size of largest nodule0.053  \<1.5 mm6/8 (75.0%)0/9 (0%)4/18 (22.2%)10/35 (28.6%)  ≥1.5 mm2/8 (25.0%)9/9 (100%)14/18 (77.8%)25/35 (71.4%)0.002   1.5--3 mm1/8 (12.5%)4/9 (44.4%)6/18 (33.3%)11/35 (31.4%)   3--10 mm1/8 (12.5%)4/9 (44.4%)6/18 (33.3%)11/35 (31.4%)   ≥10 mm0/8 (0%)1/9 (11.1%)2/18 (11.1%)3/35 (8.6%) Number0.72  15/8 (62.5%)5/9 (55.6%)11/18 (61.1%)21/35 (60.0%)  2--52/8 (25.0%)4/9 (44.4%)4/18 (22.2%)10/35 (28.6%)  \>51/8 (12.5%)0/9 (0%)3/18 (16.7%)4/35 (11.4%)Non-calcified nodule3/46 (6.5%)2/55 (3.6%)10/135 (7.4%)15/236 (6.4%)0.71Pleural thickening12/46 (26.1%)8/55 (14.5%)37/135 (27.4%)57/236 (24.2%)0.16[^5][^6][^7]Fig. 2Fibrotic scar ≥ 2 cm^2^Posteroanterior chest X-ray of a 52-year old Turkish man with diabetes mellitus and on hemodialysis. Central line in dialysis patient (black arrow). Fibrotic scar larger than 2 cm^2^ in the right upper lobe (white arrows).Fig. 2.Fig. 3Fibrotic scar ≥ 2 cm^2^ with a calcified nodule ≥ 1.5 mm78-year old female with diabetes mellitus and auto-immune disease on immunosuppression. Zoomed-in part (a) of posterioanterior chest X-ray (b) showing small 3 mm sized calcified nodule (black arrow in a, b). Fibrotic scar larger than 2 cm^2^ in the right lower lobe (white arrows, b).Fig. 3.Table 3Specific findings associated with latent tuberculosis infection.Table 3LTBI or possible LTBI *N* = 189No LTBI *N* = 44Fibrotic scar ≥ 2 cm^2^270Positive predictive value: 100%No fibrotic scar ≥ 2 cm^2^16244Negative predictive value: 21.4% (95% CI: 20.4%−22.4%)Sensitivity: 14.3% (95% CI: 9.6%−20.1%)Specificity: 100% (95% CI: 92.0%−100%)LTBI or possible LTBI *N* = 190No LTBI *N* = 46Calcified nodule ≥ 1.5 mm232[a](#tb3fn1){ref-type="table-fn"}Positive predictive value: 92.0% (95% CI: 73.8%−97.9%)No calcified nodule ≥ 1.5 mm16744Negative predictive value: 20.9% (95% CI: 19.6%−22.2%)sensitivity: 12.1% (95% CI: 7.8%−17.6%)specificity: 95.7% (95% CI: 85.2%−99.5%)[^8][^9]

3.3. Assessment by QFT or TST result {#sec0012}
------------------------------------

Individuals were also compared by QFT and TST result (Tables S1 and S2). Patients with a positive, borderline or negative QFT result were similar with regard to the presence of most abnormalities on CXR, except for a fibrotic scar ≥ 2 cm^2^ which was more often observed in patients with a borderline or positive QFT result (*p* = 0.01). If one or more calcified nodules were present (*N* = 35), then presence of a calcified nodule ≥1.5 mm was strongly associated with a borderline or positive QFT result (*p* = 0.008). No significant differences in radiological abnormalities were observed between individuals with a positive or negative TST result.

4. Discussion {#sec0013}
=============

In this study, 236 CXRs of patients in whom a QFT had been performed for various reasons were re-evaluated for prespecified lesions by a radiologist who was unaware of corresponding IGRA and TST result and final clinical diagnosis. Presence of a fibrotic scar ≥2 cm^2^ and/or a calcified nodule ≥1.5 mm were specific for LTBI or possible LTBI. In our study, all other abnormalities on CXR that have previously been reported to be characteristic of LTBI occurred in similar frequencies in patients with or without LTBI.

It is plausible that a fibrotic scar ≥2 cm^2^ and/or a calcified nodule ≥1.5 mm on CXR were specific for LTBI because these lesions reflect the result of the *Mtb*-host interaction during infection in the lung. After inhalation, *Mtb* is phagocytosed by alveolar macrophages. At the site of infection, a granuloma is formed through interaction between infected macrophages, neutrophils, B cells and T cells [@bib0017]. In case of a non-progressor, the immune response will contain bacillary growth, which eventually can result in the development of fibrotic tissue in or around the granuloma [@bib0018], [@bib0019]. This fibrotic tissue is sometimes visible on CXR and can be (partly) calcified. The size of granulomas varies depending on the extent of granulomatous inflammatory response before the containment is achieved. A calcified granuloma at the initial place of infection in the lung is named a Ghon focus, while this lesion in combination with an ipsilateral calcified hilar node is named a Ranke complex [@bib0017], [@bib0019]. Nevertheless, both a fibrotic scar and a calcified nodule have an extensive differential diagnosis. and may be present in e.g. granulomatous diseases such as sarcoidosis, bacterial or other pulmonary infections or interstitial lung diseases [@bib0012], and/or occupational lung diseases such as silicosis or pneumoconiosis, or may represent metastasis [@bib0019].

Although not pathognomonic, our data suggest that a fibrotic scar and/or a calcified nodule in combination with an increased *a priori* risk, e.g. due to *Mtb-*exposure or history of TB or LTBI, is highly suggestive of TB infection. This finding can be of added value in patients in whom it is important not to miss LTBI because of a very high risk of TB reactivation and in whom the TST and IGRA may be unreliable as a result of an impaired immune status. Only two previous studies evaluated the difference between a fibrotic scar larger or smaller than 2 cm^2^, but both lacked uninfected controls. In the first study among TST positive healthcare workers, a fibrotic scar ≥ 2 cm^2^ was associated with a positive QFT [@bib0010]. In the second study among TST positive untreated individuals, it was associated with a higher risk of development of active TB [@bib0020]. To our knowledge, our study is the first to identify calcified nodules or calcified nodules ≥ 1.5 mm as being specific for LTBI.

Roughly 50% of all included patients in our study had any prespecified abnormality on CXR considered previously associated with LTBI. Previous studies specifically aimed at assessing radiological abnormalities in individuals with or without LTBI reported a prevalence of any suggestive lesion between 4.1% and 67.9% [@bib0009], [@bib0010], [@bib0021], [@bib0022], [@bib0023], [@bib0024]. This large range was probably related to the setting and the type of lesions that were assessed in these studies. In our cohort, the prevalence of certain radiological abnormalities was higher than reported in the literature, with the exception of calcified nodules. Five previous studies assessed the frequency of predefined abnormalities on CXR [@bib0009], [@bib0010], [@bib0022], [@bib0024], [@bib0025]. In these studies, the prevalence of fibrotic scarring, calcified nodules, non-calcified nodules, and pleural thickening varied from 0% to 3.0%, 1.8% to 59.8%, 0% to 3.0%, and 0.3% to 2.7%, respectively. However, none of these studies included uninfected controls, precluding conclusions with regard to the specificity of these lesions. The differences in the prevalence rates for each abnormality between our study and earlier literature could be caused by several characteristics of our study population and the method of assessment. Firstly, nearly 20% of all patients in our study had a history of pulmonary disease, even more in the group without LTBI, which could account for various non-TB related lesions on CXR that look similar to those due to past *Mtb* infection. Secondly, except for one study [@bib0025], earlier literature described a population that consisted of asymptomatic patients screened for occupational purposes, whereas patients in our study were screened for different reasons such as possible active TB, or detecting LTBI in case of eligibility for immunosuppressive therapy. Finally, the mean age of our population was at least 10 years higher than that of patients in previous studies, resulting in a higher chance of having other unreported pulmonary conditions reflected in various lesions on CXR.

That the frequency of most predefined lesions on the CXR in individuals with and without LTBI was similar is in line with the results of several previous studies [@bib0013], [@bib0026], [@bib0027], [@bib0028], [@bib0029], [@bib0030], most of which specified the lesions considered suggestive for LTBI [@bib0013], [@bib0026], [@bib0027], [@bib0029], [@bib0030], although only one was specifically aimed at finding abnormalities on CXR [@bib0013], and the radiologist was blinded in only two studies [@bib0027], [@bib0030]. In other studies, however, predefined lesions considered suggestive for LTBI were observed significantly more frequently in patients with LTBI than in uninfected controls [@bib0011], [@bib0023], [@bib0027], [@bib0029], [@bib0031]. The assessment by the radiologist was blinded in four of these studies [@bib0011], [@bib0023], [@bib0027], [@bib0031]. However, only one study was specifically aimed to find LTBI-related abnormalities on CXR [@bib0023]. Studies in which the radiologist is aware of immunological results prior to evaluating a CXR are subject to potential observer bias, as a radiologist can be more inclined to register minor abnormalities in patients with a positive TST or IGRA result. The strength of our study was that the radiologist was blinded to all immunological results and final clinical diagnosis. The lack of a second observer was a limitation, but a previous study demonstrated high inter-observer agreement between radiologists [@bib0010].

Another limitation of our study was that the study population included a disproportionally large number of individuals with a QFT result around the cut-off (0.15--0.70 IU/ml) and only a limited number of patients with a high positive QFT, as participants had been selected with the focus on borderline QFT results [@bib0015]. Therefore, it would be useful to repeat our study in a population reflecting the natural distribution of QFT results. Inclusion of more patients with a high positive QFT is expected to result in more pronounced differences between groups and may reveal additional lesions specific for LTBI. Interestingly, the presence of a fibrotic scar ≥2 cm^2^ and/or a calcified nodule ≥1.5 mm on CXR was found as often in individuals with possible LTBI (borderline QFT result with negative or no TST) as in those with LTBI. This corroborates the findings from previous studies in which it was demonstrated that most borderline QFT results reflect infection with *Mtb* as opposed to random assay variability [@bib0015], [@bib0032], [@bib0033].

In general, finding abnormalities of LTBI on a CXR can occur in three different settings. First, if a CXR is made to assess for possible active TB after a positive TST or IGRA result during screening for LTBI. Here, findings suggestive for LTBI have no added value since preventive therapy is guided by the positive immune test. A second setting is when lesions on CXR suspect for possible LTBI can be an incidental finding in patient in whom CXR is made for other purposes. If the patient is or will be at risk of TB reactivation, e.g. as a result of immunosuppressive therapy, treatment of LTBI may be indicated. The third situation, in which CXR can be of particular value, is when patients are screened for LTBI because of (planned) immunosuppression with drugs such as TNF antagonists or those used for prevention of rejection after organ transplantation, and in whom a suppressed or waned immune response can result in false negative TST or IGRA results [@bib0008], [@bib0034], [@bib0035]. Importantly, negative IGRA results include borderline QFT results and it has previously been demonstrated that the majority of individuals with a borderline QFT are actually infected with *Mtb,* which is highly relevant if immunosuppression is planned [@bib0015], [@bib0032], [@bib0033]. A case of disseminated TB during treatment with infliximab, and who in retrospect had a borderline QFT result, illustrates that the sensitivity of screening methods in this setting can be improved [@bib0036]. Nevertheless, the CXR has suboptimal sensitivity for LTBI, even for calcified nodules [@bib0037]. In that regard, computed tomography (CT) had a higher sensitivity and a high concordance rate with IGRA results [@bib0006], [@bib0038]. Because CT findings carry the risk of more false positive results it is of utmost importance to better define which lesions on CT are specific for TB infection. Computer-aided detection of active pulmonary TB on CXR has been studied [@bib0039], [@bib0040]. Thus far this has not yet been done for detection of LTBI, but this could be considered if the highly specific lesions observed in our study can be confirmed.

5. Conclusion {#sec0014}
=============

In conclusion, a fibrotic scar ≥ 2 cm^2^ and/or a calcified nodule ≥1.5 mm on CXR were specifically associated with prior TB infection. Finding such lesions is clinically relevant in patients who are at high risk of TB reactivation and in whom results of TST and IGRA may be false negative.
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[^1]: Continuous variables are displayed as mean ± SD, categorical values are displayed as numerator over denominator (%).

[^2]: Abbreviations: TB: tuberculosis; BCG: Bacille Calmette-Guérin; TST: tuberculin skin test; QFT-GIT: QuantiFERON-TB Gold In-Tube; LTBI: latent tuberculosis infection; IGRA: interferon-gamma release assays; CXR: chest radiography.

[^3]: Defined as country with TB incidence ≥50 cases of active tuberculosis/100,000 inhabitants.

[^4]: As explained in the methods.

[^5]: Continuous variables are displayed as mean ± SD, categorical values are displayed as numerator over denominator (%).

[^6]: Abbreviations: LTBI: latent tuberculosis infection; QFT: QuantiFERON-TB Gold In-Tube; BCG: Bacille Calmette-Guérin; TB: tuberculosis; COPD: chronic obstructive pulmonary disease.

[^7]: The size of the fibrotic scar could not be assessed reliably in three cases due to other acute pathology (*N* = 2) or pre-existent familial pulmonary fibrosis (*N* = 1).

[^8]: Abbreviations: LTBI: latent tuberculosis infection; CI: confidence interval.

[^9]: In both cases no tuberculin skin test had been performed.
